睿智医药涨2.18%，成交额1.83亿元，主力资金净流入743.36万元

Core Viewpoint - The stock of Ruizhi Pharmaceutical has shown significant growth this year, with a notable increase in both share price and trading volume, indicating strong market interest and investor confidence [2][3]. Group 1: Stock Performance - As of September 9, Ruizhi Pharmaceutical's stock price increased by 2.18%, reaching 14.05 CNY per share, with a trading volume of 1.83 billion CNY and a market capitalization of 69.96 billion CNY [1]. - Year-to-date, the stock price has risen by 118.85%, with recent trading performance showing an 8.58% increase over the last five trading days, an 11.24% increase over the last 20 days, and a 20.70% increase over the last 60 days [2]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on July 29, where it recorded a net purchase of 1.65 billion CNY [2]. Group 2: Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 5.34 billion CNY, reflecting a year-on-year growth of 14.75%, while the net profit attributable to shareholders was 25.38 million CNY, marking a substantial increase of 140.35% [3]. - The company has cumulatively distributed 1.80 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [4]. Group 3: Shareholder and Ownership Structure - As of August 8, the number of shareholders for Ruizhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period, while the average number of tradable shares per person increased by 23.28% to 9,038 shares [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 24.33 million shares, with no change in the number of shares held compared to the previous period [4]. Group 4: Business Overview - Ruizhi Pharmaceutical, established on January 26, 2000, and listed on December 22, 2010, is primarily engaged in pharmaceutical research and production outsourcing services, with 99.06% of its revenue derived from these services [2]. - The company operates within the pharmaceutical and biotechnology sector, focusing on medical services and research outsourcing, and is associated with concepts such as CRO, innovative drugs, biopharmaceuticals, AI medicine, and cancer treatment [2].